Docetaxel, cisplatin and 5-fluorouracil-based induction chemotherapy followed by intensity-modulated radiotherapy concurrent with cisplatin in locally advanced EBV-related nasopharyngeal cancer

Annals of Oncology

Volumn 22, Issue 11, 2011, Pages 2495-2500

  Bossi, P ^a   Orlandi, E ^a   Bergamini, C ^a   Locati, L D ^a   Granata, R ^a   Mirabile, A ^a   Franceschini, D Parolini ^a   Fallai, C ^a   Olmi, P ^a   Quattrone, P ^a   Potepan, P ^a   Gloghini, A ^a   Miceli, R ^a   Mattana, F ^a   Scaramellini, G ^a   Licitra, L ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Cisplatin; Docetaxel; Induction chemotherapy; Intensity modulated radiotherapy; Nasopharyngeal carcinoma

Indexed keywords

CARBOPLATIN; CIPROFLOXACIN; CISPLATIN; DOCETAXEL; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ADVANCED CANCER; ANEMIA; ARTICLE; CANCER GRADING; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DERMATITIS; DIARRHEA; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DYSGEUSIA; DYSPHAGIA; EPSTEIN BARR VIRUS; FEBRILE NEUTROPENIA; FEMALE; FIBROSIS; GASTROINTESTINAL TOXICITY; HEARING LOSS; HUMAN; HYPOKALEMIA; HYPOTHYROIDISM; INTENSITY MODULATED RADIATION THERAPY; MALE; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NASOPHARYNX CANCER; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SENSORY NEUROPATHY; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TOOTH DISEASE; TREATMENT RESPONSE; VOICE CHANGE; VOMITING; XEROSTOMIA;

EID: 80155124275     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq783     Document Type: Article

References (36)

1. Lee N, Harris J, Garden AS et al. Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225. J Clin Oncol 2009; 27: 3684-3690.
2. Lin S, Lu JJ, Han L et al. Sequential chemotherapy and intensity-modulated radiation therapy in the management of locoregionally advanced nasopharyngeal carcinoma: experience of 370 consecutive cases. BMC Cancer 2010; 10: 39.
3. Tham IW, Hee SW, Yeo RM et al. Treatment of nasopharyngeal carcinoma using intensity-modulated radiotherapy-the National Cancer Centre Singapore experience. Int J Radiat Oncol Biol Phys 2009; 75: 1481-1486.
4. Wolden SL, Chen WC, Pfister DG et al. Intensity-modulated radiation therapy (IMRT) for nasopharynx cancer: update of the Memorial Sloan-Kettering experience. Int J Radiat Oncol Biol Phys 2006; 64: 57-62.
5. Baujat B, Audry H, Bourhis J et al. Chemotherapy in locally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis of eight randomized trials and 1753 patients. Int J Radiat Oncol Biol Phys 2006; 64: 47-56.
6. Langendijk JA, Leemans CR, Buter J et al. The additional value of chemotherapy to radiotherapy in locally advanced nasopharyngeal carcinoma: a meta-analysis of the published literature. J Clin Oncol 2004; 22: 4604-4612.
7. Chan AT, Felip E. Nasopharyngeal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009; 20 (Suppl 4): 123-125.
8. Cvitkovic E, Eschwege F, Rahal M et al. Preliminary results of a randomized trial comparing neoadjuvant chemotherapy (cisplatin, epirubicin, bleomycin) plus radiotherapy vs. radiotherapy alone in stage IV(> or = N2, M0) undifferentiated nasopharyngeal carcinoma: a positive effect on progression-free survival. International Nasopharynx Cancer Study Group. VUMCA I trial. Int J Radiat Oncol Biol Phys 1996; 35: 463-469.
9. Chan AT, Teo PM, Leung TW et al. A prospective randomized study of chemotherapy adjunctive to definitive radiotherapy in advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 1995; 33: 569-577.
10. Chua DT, Sham JS, Choy D et al. Preliminary report of the Asian-Oceanian Clinical Oncology Association randomized trial comparing cisplatin and epirubicin followed by radiotherapy versus radiotherapy alone in the treatment of patients with locoregionally advanced nasopharyngeal carcinoma. Asian-Oceanian Clinical Oncology Association Nasopharynx Cancer Study Group. Cancer 1998; 83: 2270-2283.
11. Hareyama M, Sakata K, Shirato H et al. A prospective, randomized trial comparing neoadjuvant chemotherapy with radiotherapy alone in patients with advanced nasopharyngeal carcinoma. Cancer 2002; 94: 2217-2223.
12. Ma J, Mai HQ, Hong MH et al. Results of a prospective randomized trial comparing neoadjuvant chemotherapy plus radiotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma. J Clin Oncol 2001; 19: 1350-1357.
13. Chua DT, Ma J, Sham JS et al. Long-term survival after cisplatin-based induction chemotherapy and radiotherapy for nasopharyngeal carcinoma: a pooled data analysis of two phase III trials. J Clin Oncol 2005; 23: 1118-1124.
14. Hui EP, Ma BB, Leung SF et al. Randomized phase II trial of concurrent cisplatinradiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma. J Clin Oncol 2009; 27: 242-249.
15. Haddad R, Colevas AD, Tishler R et al. Docetaxel, cisplatin, and 5-fluorouracilbased induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience. Cancer 2003; 97: 412-418.
16. Posner MR, Hershock DM, Blajman CR et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007; 357: 1705-1715.
17. Vermorken JB, Remenar E, van Herpen C et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007; 357: 1695-1704.
18. Greene FL, Page DL, Fleming ID, Fritz A et al. (eds) AJCC Cancer Staging Manual, 6th edn. New York: Springer-Verlag 2002.
19. National Cancer Institute. Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events. Version 3.0. DCTD, NCI, NIH, DHHS 2006; http://ctep.cancer.gov/ (2 March 2011, date last accessed).
20. Bernier J, Cooper JS, Pajak TF et al. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck 2005; 27: 843-850.
21. Al-Sarraf M, LeBlanc M, Giri PG et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol 1998; 16: 1310-1317.
22. Lefebvre J, Pointreau Y, Rolland F et al. Sequential chemoradiotherapy (SCRT) for larynx preservation (LP): preliminary results of the randomized phase II TREMPLIN study. J Clin Oncol 2009; 27: 15s (Suppl; Abstr 6010).
23. Al-Amro A, Al-Rajhi N, Khafaga Y et al. Neoadjuvant chemotherapy followed by concurrent chemo-radiation therapy in locally advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2005; 62: 508-513.
24. Chan AT, Ma BB, Lo YM et al. Phase II study of neoadjuvant carboplatin and paclitaxel followed by radiotherapy and concurrent cisplatin in patients with locoregionally advanced nasopharyngeal carcinoma: therapeutic monitoring with plasma Epstein-Barr virus DNA. J Clin Oncol 2004; 22: 3053-3060.
25. Ferrari D, Chiesa F, Codeca C et al. Locoregionally advanced nasopharyngeal carcinoma: induction chemotherapy with cisplatin and 5-fluorouracil followed by radiotherapy and concurrent cisplatin: a phase II study. Oncology 2008; 74: 158-166.
26. Lee AW, Lau KY, Hung WM et al. Potential improvement of tumor control probability by induction chemotherapy for advanced nasopharyngeal carcinoma. Radiother Oncol 2008; 87: 204-210.
27. Oh JL, Vokes EE, Kies MS et al. Induction chemotherapy followed by concomitant chemoradiotherapy in the treatment of locoregionally advanced nasopharyngeal cancer. Ann Oncol 2003; 14: 564-569.
28. Rischin D, Corry J, Smith J et al. Excellent disease control and survival in patients with advanced nasopharyngeal cancer treated with chemoradiation. J Clin Oncol 2002; 20: 1845-1852.
29. Yau TK, Lee AW, Wong DH et al. Treatment of stage IV (A-B) nasopharyngeal carcinoma by induction-concurrent chemoradiotherapy and accelerated fractionation: impact of chemotherapy schemes. Int J Radiat Oncol Biol Phys 2006; 66: 1004-1010.
30. Lee SW, Back GM, Yi BY et al. Preliminary results of a phase I/II study of simultaneous modulated accelerated radiotherapy for nondisseminated nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2006; 65: 152-160.
31. Kwong DL, Sham JS, Leung LH et al. Preliminary results of radiation dose escalation for locally advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2006; 64: 374-381.
32. Orlandi E, Palazzi M, Pignoli E et al. Radiobiological basis and clinical results of the simultaneous integrated boost (SIB) in intensity modulated radiotherapy (IMRT) for head and neck cancer: a review. Crit Rev Oncol Hematol 2010; 73: 111-125.
33. Kim K, Wu HG, Kim HJ et al. Intensity-modulated radiation therapy with simultaneous integrated boost technique following neoadjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma. Head Neck 2009; 31: 1121-1128.
34. Bae WK, Hwang JE, Shim HJ et al. Phase II study of docetaxel, cisplatin, and 5-FU induction chemotherapy followed by chemoradiotherapy in locoregionally advanced nasopharyngeal cancer. Cancer Chemother Pharmacol 2010; 65: 589-595.
35. Yau TK, Lee AW, Wong DH et al. Induction chemotherapy with cisplatin and gemcitabine followed by accelerated radiotherapy and concurrent cisplatin in patients with stage IV (A-B) nasopharyngeal carcinoma. Head Neck 2006; 28: 880-887.
36. Lin JC, Wang WY, Chen KY et al. Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med 2004; 350: 2461-2470